Antibody-Drug Conjugates in HER2-Positive Breast Cancer
August 14th 2020Novel antibody-drug conjugates introduce promising options for the management of patients with HER2-positive breast cancer; however, management of drug-related toxicities and optimal sequencing of HER2-targeted therapies remains an ongoing challenge.